enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Uncommon Signs of Diabetes Doctors Want You to Know - AOL

    www.aol.com/uncommon-signs-diabetes-doctors-want...

    Endocrinologists share uncommon symptoms of diabetes that may indicate type 1, type 2, or prediabetes. Some signs include infections and dry skin.

  3. FDA warns consumers to stop using Hydroxycut: one dead, 23 ...

    www.aol.com/2009/05/01/fda-warns-consumers-to...

    The heavily marketed diet product line Hydroxycut has been blamed in the death of at least one person and for nearly two dozen serious ailments, prompting the U.S. Food and Drug Administration to ...

  4. Hydroxycut - Wikipedia

    en.wikipedia.org/wiki/Hydroxycut

    Hydroxycut is a brand of dietary supplements that is marketed as a weight loss aid. Hydroxycut was originally developed and manufactured by MuscleTech Research and Development; MuscleTech was sold to Iovate Health Sciences in 2003–2004 and declared bankruptcy in 2005; Iovate continues to use MuscleTech as a brand to market Hydroxycut.

  5. Talk:Hydroxycut/Archive 1 - Wikipedia

    en.wikipedia.org/wiki/Talk:Hydroxycut/Archive_1

    On May 1, 2009, the FDA issued a warning to consumers to stop using Hydroxycut products, due to 23 reports of serious health problems associated with the use of Hydroxycut, and at least one death. The FDA cited a total of 23 case reports of Hydroxycut-associated liver toxicity in their CAERS database over a seven year period from 2002 to the ...

  6. FDA recalls popular diabetes care app after glitches result ...

    www.aol.com/news/fda-recalls-popular-diabetes...

    A glitch in a version of Tandem Diabetes Care's Apple iOS app that is used with certain insulin pumps has led to over 200 injuries, prompting the FDA to issue a recall.

  7. Dipeptidyl peptidase-4 inhibitor - Wikipedia

    en.wikipedia.org/wiki/Dipeptidyl_peptidase-4...

    A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.

  8. Should You Skip Your Weight-Loss Injectable to Enjoy Holiday ...

    www.aol.com/lifestyle/skip-weight-loss-inject...

    Related: Mounjaro Is 'Significantly' More Effective for Weight Loss Than Ozempic, Study Says Plus, your body is simply not used to that level of consumption. “You can't just assume that, ‘Oh ...

  9. Insulitis - Wikipedia

    en.wikipedia.org/wiki/Insulitis

    Insulitis, which is present in roughly 19% of type 1 diabetes patients, most prominently occurs in the first year after diagnosis in patients aged 0 to 14 years with a prevalence of 68% (32/47 patients studied). [1] Insulitis prevalence is 4% in young patients with chronic type 1 diabetes (patients who have had the disease for over a year). [1]